Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Deafness and Other Communication Disorders (NIDCD) National Institute on Aging (NIA) |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00537004 |
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
Condition |
---|
Primary Progressive Aphasia |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Language in Primary Progressive Aphasia |
Estimated Enrollment: | 120 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | April 2012 |
Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
PPA
Individuals with primary progressive aphasia
|
Control
Individuals with no diagnosis of any type of dementia
|
The study's main goal is to gain a better understanding of the progression and characterization of primary progressive aphasia (PPA). To do this, we look at many different aspects of the disease: neurological, defined by a clinical exam and MRI; neuropsychological, defined by a large battery of tests examining memory, attention, naming, and others; and linguistic, measured through picture, word, and sentence comprehension.
Volunteers with PPA will participate for three days; control volunteers will only participate for two. On the first day, each participant will come to the Chicago campus of Northwestern University to complete the neuropsychological testing battery developed by the researchers involved in the study. Also, on day one, the participant will be asked to have an MRI for imaging purposes.
On days two and three (or just day two, if a control participant), the participant will perform tasks on a computer in which they are presented with pictures on a screen and be asked to respond appropriately, based on study instructions. Also, the participant will be asked to perform a task while connected to an EEG to record event related potentials.
15 PPA and 15 Control participants will be recruited each year for four years. Those participating in years one and two will return in years three and four, respectively, to look at progression. Participants recruited in years three and four will only participate in the study once.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Primarily individuals enrolled in the Memory Research Core of NU's Cognitive Neurology and Alzheimer's Disease center. The minority are individuals who have contacted the Center for information about PPA research.
Inclusion Criteria:
Exclusion Criteria:
Contact: Christina Wieneke | 312-908-9681 | c-wieneke@northwestern.edu |
United States, Illinois | |
Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Christina Wieneke 312-908-9681 c-wieneke@northwestern.edu | |
Principal Investigator: M.-Marsel Mesulam, MD | |
Sub-Investigator: Sandra Weintraub, PhD |
Principal Investigator: | M.-Marsel Mesulam | Northwestern University Feinberg School of Medicine |
Responsible Party: | Northwestern University, Cognitive Neurology and Alzheimer's Disease Center ( Marsel Mesulam, MD, Professor ) |
Study ID Numbers: | IA0125, 1RO1DC008552-01 |
Study First Received: | September 26, 2007 |
Last Updated: | December 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00537004 |
Health Authority: | United States: Federal Government |
Mesulam syndrome dementia Mild Cognitive Impairment |
Pick Disease of the Brain Speech Disorders Frontotemporal dementia Aphasia Language Disorders Central Nervous System Diseases Brain Diseases Aphasia, Primary Progressive Cognition Disorders Signs and Symptoms |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Neurologic Manifestations Lobar atrophy of brain Primary progressive aphasia Dementia Neurobehavioral Manifestations Pick disease of the brain Communication Disorders Delirium |
Nervous System Diseases |